bioRxivCancer BiologyPreprint
Depletion of BRCA1 Potentiates Progestin-Induced Cytoskeletal Changes in an Ovarian Cancer Cell Model
Jocelyn Baquier, Noelle E. GillisiD, Caroline H. DiepiD, Laura J. MauroiD, Carol Ann LangeiD
Abstract
Individuals with Hereditary Breast and Ovarian Cancer (HBOC) syndrome carry BRCA1/2 mutations that predispose them to various cancers. Notably, this condition increases the risk of developing an aggressive ovarian cancer (OC) subtype known as high-grade serous ovarian cancer (HGSOC). The impact of progesterone (P4) on the development of OC subtypes remains unclear. Research suggests a potential interplay between Progesterone Receptor (PR) signaling and BRCA1/2 actions. BRCA1 regulates PR expression and transcriptional activity, while P4 can drive estrogen receptor/PR complexes to BRCA1 DNA binding motifs. Normal fallopian tube tissues from healthy BRCA1/2 carriers (the cells of origin for HGSOC) exhibit gene signatures similar to those in HGSOC only during the luteal phase of the menstrual cycle, when circulating P4 levels are elevated. This implies a potential role for PR/BRCA complexes in modulating OC initiation and progression. To explore this interaction, BRCA1 was depleted in an ES-2 PR-B+ OC cell models using CRISPR-mediated gene editing. We hypothesized that BRCA1 depletion would alter PR-mediated signaling and reveal novel regulatory mechanisms. Depletion of BRCA1 led to increased total basal PR protein levels and site-specific hyperphosphorylation at S294 and S81 following R5020 (synthetic progestin) treatment. RNA sequencing of NE-1 and KO-BRCA1 pools treated with R5020 identified a high-confidence set of BRCA1-dependent, R5020-induced genes predominately involved with migration and cytoskeletal organization. Transwell assays revealed that R5020 treatment stimulates migration, an effect amplified upon BRCA1 depletion. Inhibition of PIP5K1C using UNC3230 blocked R5020-induced migration in one of the KO-BRCA1 cell pools with pan-Rho inhibitor CT04 showing similar results. The Rac1 inhibitor EHT-1864 suppressed all R5020-induced migration. In contrast, co-treatment with a pan-ROCK1/2 inhibitor Y-27632 resulted in an increase in R5020-induced migration, which was further enhanced with BRCA1 depletion. Overall, these findings establish a crosstalk between BRCA1 and PR signaling, where BRCA1 depletion sensitizes OC cells to progestin-induced migration by altering PR phosphorylation and remodeling cytoskeletal organization via PIP5K1C, Rho-GTPase, and Rac1-dependent mechanisms.
- organism: human
- assay: bulk RNA-seq
- research focus: cell signaling & trafficking
- approach: genetic perturbation / CRISPR
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Somatic aberrations of BRCA1 gene are associated with progressive and stem cell-like phenotype of prostate cancer
Aleksandra Omari, Paulina Nastały, … Natalia Bednarz-Knoll·bioRxiv·Feb 26, 2018
- BRCA1 expression, its correlation with clinicopathological features and response to neoadjuvant chemotherapy in high grade serous ovarian cancer from an Indian centre
A. Patil, S. Patil, … J. S. Prabhu·bioRxiv·Jan 11, 2023
- Functionality of BRCA1 supports the survival of prostate cancer cells during the development of castration resistance
Saiganesh Sriraman, Verneri Virtanen, … Maria Sundvall·bioRxiv·Jun 19, 2024
- Constitutive Expression of the Progesterone Receptor Isoforms Promotes Hormone-Dependent Development of Ovarian Neoplasms
M. Wetendorf, R. Li, … F. J. DeMayo·bioRxiv·Oct 24, 2019
- Breast cancer cells can recognize and respond to different levels of progestins to achieve different phenotypic outputs
E. L. Dolan, R. Safi, … D. P. McDonnell·bioRxiv·Oct 13, 2023
- Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editing
Ksenija Nesic, Sally Beard, … Matthew J. Wakefield·bioRxiv·Sep 23, 2024